We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Slaps Lupin With Form 483 for Risk of Contamination, Lack of In-Process Testing
FDA Slaps Lupin With Form 483 for Risk of Contamination, Lack of In-Process Testing
Inadequate procedures to minimize the risk of contamination earned Lupin Limited a Form 483 following a March 22 to April 4 FDA inspection of its facility in Palghar, Maharashtra, India.
